Enterobactin inhibits microbiota-dependent activation of AhR to promote bacterial sepsis in mice

Robert C Keskey1,2, Jason Xiao3, Sanjiv Hyoju4

  • 1Section of General Surgery, Department of Surgery, University of Chicago, Chicago, IL, USA. rkeskey@uchicagomedicine.org.

Nature Microbiology
|January 8, 2025
PubMed

Insights

Gut microbiota metabolites, like indoles, enhance survival in sepsis by activating the aryl hydrocarbon receptor (AhR). Pathogen-secreted enterobactin inhibits AhR, increasing sepsis mortality, highlighting a critical host-microbe interaction for survival.

Area of Science:

  • Microbiology
  • Immunology
  • Metabolomics

Background:

  • Sepsis significantly contributes to mortality and morbidity, with limited understanding of survival mechanisms.
  • Pathogen subversion of host defenses may critically influence sepsis outcomes.
  • The role of host-microbiota interactions in sepsis pathogenesis is increasingly recognized.

Purpose of the Study:

  • To investigate the influence of gut microbiota and their metabolites on host survival during sepsis.
  • To elucidate the role of the aryl hydrocarbon receptor (AhR) pathway in sepsis.
  • To identify pathogen-derived factors that may counteract host protective mechanisms.

Main Methods:

  • Utilized a mouse model of Serratia marcescens sepsis.
  • Employed microbiota analysis, fecal microbiota transplantation, and antibiotic treatment.
  • Conducted caecal metabolite analysis, macrophage-specific AhR knockout studies, and in vitro assays.

Main Results:

  • Gut microbiota-derived tryptophan metabolites, including indoles, enhanced host survival in a mouse sepsis model.
  • Activation of the aryl hydrocarbon receptor (AhR) in macrophages increased bacterial clearance and survival.
  • Bacterial pathogen culture supernatants, specifically the siderophore enterobactin, inhibited AhR activation and increased sepsis mortality.
  • Oral or systemic tryptophan supplementation improved host survival.

Conclusions:

  • Sepsis survival is critically dependent on the balance between pathogen-derived inhibitors and microbiota-derived activators of the AhR pathway.
  • Tryptophan metabolites and AhR activation represent potential therapeutic targets for sepsis.
  • Understanding host-microbe-metabolite interactions is crucial for developing novel sepsis treatments.